Curcumin (research-only chemoprevention candidate — not standard-of-care)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CURCUMIN-CHEMOPREVENTION |
|---|---|
| Type | Drug |
| Aliases | Curcumin chemopreventionDiferuloylmethaneTurmeric extract (Curcuma longa) — standardized curcuminoidsvarious OTC supplements — Meriva, Theracurmin, BCM-95, Longvida (lipidic / phytosomal forms)Куркумін (дослідницький кандидат для хіміопрофілактики — НЕ стандарт) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-GENETIC-FAMILIAL-CRC-2025 SRC-WCRF-AICR-CUP-2018 |
Drug Facts
| Class | Polyphenol / curcuminoid — dietary supplement (food-grade phytochemical) |
|---|---|
| Mechanism | Hydrophobic polyphenol from Curcuma longa rhizome (turmeric). In vitro and animal studies report pleiotropic anti-inflammatory, antioxidant, and antiproliferative activity: inhibition of NF-κB, STAT3, AP-1, COX-2, and 5-LOX signaling; induction of apoptosis in cancer cell lines; modulation of Wnt/β-catenin, Notch, and Hedgehog pathways. Cancer-prevention rationale: rich preclinical signal across colorectal, breast, pancreatic, prostate, and skin cancer models. Translation to human prevention is severely limited by very poor oral bioavailability (~1% as native curcumin; rapid glucuronidation/sulfation). Most clinical trials are small (n<100), short, and use surrogate endpoints (e.g., aberrant crypt foci in FAP — Cruz-Correa 2018 showed no benefit on polyp number at 12 months vs. placebo). No completed phase-III primary-prevention RCT supports routine use. |
| Typical dosing | RESEARCH-ONLY / NOT GUIDELINE-RECOMMENDED: Standardized curcuminoid extract 500-2000 mg PO daily, often as divided doses with food and lipid (improves absorption ~3-fold). Bioavailability-enhanced formulations (phytosomal / liposomal / nano-particulate) at lower mg-equivalents have been tested in small trials. No accepted "chemoprevention dose" — no clinical trial network has established a regimen suitable for routine use. Maximum reasonable supplemental dose generally <8 g/day per EFSA acceptable daily intake. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 chemoprevention-workstream authoring (batch 2); pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. CURCUMIN IS NOT STANDARD-OF-CARE CHEMOPREVENTION (research-only context). Preclinical signal is broad and consistent across cell-line and rodent models, but clinical translation is severely limited by poor oral bioavailability and lack of phase-III prevention RCTs. CRUZ- CORREA 2018 — FAP RCT, curcumin 3 g/day vs. placebo × 1 year, NO effect on duodenal polyp number/size. Other small RCTs report inconsistent surrogate-endpoint results in colorectal aberrant-crypt- foci, breast biomarkers, prostate PSA kinetics. PHARMACOVIGILANCE CONCERN: rising case reports of curcumin/turmeric-supplement- associated acute hepatitis 2022-2024 (particularly bioavailability- enhanced formulations and piperine-combined products). NO regulatory body (FDA, EMA, USPSTF, NCCN, ASCO, WCRF-AICR) recommends curcumin supplementation for cancer prevention. ENGINE MUST NOT recommend curcumin chemoprevention; entity exists to (a) document non-standard- of-care status in the catalog and (b) support active counseling away from OTC chemoprevention marketing claims. Standardized curcuminoid pr...
Used By
No reverse references found in the YAML corpus.